
News|Articles|October 26, 2012
FDA approves Synribo for chronic myelogenous leukemia
FDA has approved omacetaxine mepesuccinate (Synribo, Teva) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease. An estimated 5,430 people will be diagnosed with CML in 2012, according to the National Institutes of Health. Synribo is intended to be used in patients whose cancer progressed after treatment with at least 2 drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare’s first-year payments for social needs showed high use by primary care but many claims were denied
2
See which Minnesota healthcare CEOs signed letter calling for 'immediate deescalation of tensions' following shooting of Alex Pretti
3
House passes funding bill that includes PBM reform
4
Do you know what’s in your contracts?
5




























